Skip to main content
. 2021 Jan 13;129(1):017002. doi: 10.1289/EHP7310

Figure 1.

Figure 1 is a flow chart depicting Phase 1 spring per summer 2018 and Phase 2 Autumn 2018. Phase 1 spring per summer 2018 has seven steps. Step 1: Recruitment lowercase italic n equals 488. Step 2: Saliva kits sent out lowercase italic n equals 445. Step 3: Saliva kits back lowercase italic n equals 432. Step 4: Genotyping filaggrin gene null lowercase italic n equals 432 (percent filaggrin gene null equals 6.45). Step 5: Invite filaggrin gene null carriers lowercase italic n equals 28 plus sex and age matched filaggrin gene wild-type carriers. Step 6: 5 filaggrin gene null carriers declined participation phase 2. Step 7: Re-genotyping of selected participants. Phase 2 Autumn 2018 has three steps. Step 1: Re-genotyping of selected participants leads to dermal exposure experiment filaggrin gene null lowercase italic n equals 23, filaggrin gene wild-type lowercase italic n equals 31 asterisk. Step 2: 1) Pre-exposure: blood plus urine samples, 2) Exposure on arms to: oxybenzone (start of exposure), pyrene, and pyrimethanil. Cover with aluminum foil plus mefix tape, 3) Remove cover approx. 4 hours after start, wash 3 times w. swabs plus 70 percent ethanol (end of exposure), wash w. water plus soap, and 4) Post-exposure: blood samples after end of exposure, urine collection for 48 hours. Step 3: Liquid chromatography mass spectrometry of metabolites per compound in urine genetic analysis (copy number variants).

Flow chart of the two phases of the exposure experiment. Note: *8 extra wt carriers were included.